高原地区使用达格列净致正常血糖酮症酸中毒1例分析

doi:10.19803/j.1672-8629.20260364

中国药物警戒 ›› 2026, Vol. 23 ›› Issue (10): 1175-1177.
DOI: 10.19803/j.1672-8629.20260364

高原地区使用达格列净致正常血糖酮症酸中毒1例分析

王焕萍, 方威, 朱红霞^*

成都市双流区中医医院内分泌科,四川成都 610072

收稿日期:2026-05-06 出版日期:2026-10-15 发布日期:2026-10-16
通讯作者: ^*朱红霞,女,硕士,主任医师,内分泌相关临床研究。E-mail: 2780019047@qq.com
作者简介:王焕萍,女,硕士,主治医师,内分泌相关临床研究。
基金资助:
成都市医学科研课题（2024313、2026509）;北京微爱公益基金-阿格列汀联合加味葛根芩连汤治疗二甲双胍疗效不佳的2型糖尿病随机对照研究

One case of euglycemic diabetic ketoacidosis caused by dapagliflozin used at a high altitude

Wang Huanping, Fang Wei, Zhu Hongxia^*

Department of Endocrinology, Chengdu Shuangliu Hospital of Traditional Chinese Medicine, Chengdu Sichuan 610072, China

Received:2026-05-06 Online:2026-10-15 Published:2026-10-16

摘要/Abstract

摘要： 目的探讨高原地区使用达格列净致正常血糖酮症酸中毒（euDKA）的不良反应,为临床安全合理用药提供参考。方法分析1例26岁久居高原的2型糖尿病患者长期服用达格列净后发生euDKA病例,结合文献复习探讨其危险因素与防治策略。结果入院后立即停用达格列净,并予补液、小剂量胰岛素治疗,酸中毒纠正,酮体转阴。经关联性评价,euDKA与达格列净的因果关系为“很可能”。结论高原低氧环境下使用达格列净可能增加euDKA风险,临床须提高警惕,早期识别处理,保障用药安全。

关键词: 达格列净, 钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）, 正常血糖酮症酸中毒, 高原低氧, 药品不良反应

Abstract: Objective To investigate the adverse drug reaction of euglycemic diabetic ketoacidosis (euDKA) associated with dapagliflozin used in high-altitude areas in order to provide a reference for safe and rational drug use. Methods A case of euDKA in a 26 year old type 2 diabetes patient with long term high altitude residence and after prolonged use of dapagliflozin was analyzed. The risk factors and strategies for prevention and treatment were studied based on literature review. Results Dapagliflozin was discontinued immediately after admission, and the patient received fluid resuscitation and low dose intravenous insulin. The acidosis was corrected and ketones turned negative. Based on correlation analysis, the causal relationship between dapagliflozin and euDKA was determined as “probable”. Conclusion The use of dapagliflozin in high-altitude hypoxic environments may elevate the risk of euDKA, warranting increased clinical vigilance, prompt identification, and immediate interventions to ensure safe medication.

Key words: Dapagliflozin, SGLT2 Inhibitor, Euglycemic Diabetic Ketoacidosis, High Altitude Hypoxia, Adverse Drug Reaction

中图分类号:

王焕萍, 方威, 朱红霞. 高原地区使用达格列净致正常血糖酮症酸中毒1例分析[J]. 中国药物警戒, 2026, 23(10): 1175-1177.

Wang Huanping, Fang Wei, Zhu Hongxia. One case of euglycemic diabetic ketoacidosis caused by dapagliflozin used at a high altitude[J]. Chinese Journal of Pharmacovigilance, 2026, 23(10): 1175-1177.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20260364

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I10/1175

参考文献

[1] Chinese Diabetes Society.Guidelines for the prevention and treatment of type 2 diabetes mellitus in China (2024 edition)[J]. Chinese Journal of Diabetes Mellitus(中国糖尿病杂志), 2025, 17(1): 16-139.
[2] American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024[J]. Diabetes Care, 2024, 47(Suppl 1): S158-S178.
[3] Yoshida Y, Fujimoto Y, Konishi H, et al.Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes and preserved insulin secretion on empagliflozin[J]. Internal Medicine, 2025, 64(14): 2183-2188.
[4] He Z, Lam K, Zhao W, et al.SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigi-lance assessment[J]. Acta Diabetologica, 2023, 60(3): 401-411.
[5] Goldenberg R M, Berard L D, Cheng A Y Y, et al. SGLT2 inhibitor-associated diabetic ketoacidosis: Clinical review and recommendations for prevention and diagnosis[J]. Clinical Therapeutics, 2016, 38(12): 2654-2664. e1.
[6] Morace C, Lorello G, Bellone F, et al.Ketoacidosis and SGLT2 inhibitors: a narrative review[J]. Metabolites, 2024, 14(5): 264.
[7] Xi L, Chow C M, Kong X.Role of tissue and systemic hypoxia in obesity and type 2 diabetes[J]. Journal of Diabetes Research, 2016, 2016: 1527852.
[8] Albogami S, Hassan A, Abdel-Aziem S H, et al. Effects of combination of obesity, diabetes, and hypoxia on inflammatory regulating genes and cytokines in rat pancreatic tissues and serum[J]. PeerJ, 2022, 10: e13990.
[9] Long B, Lentz S, Koyfman A, et al.Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management[J]. American Journal of Emergency Medicine, 2021, 44: 157-160.
[10] Blau J E, Tella S H, Taylor S I, et al.Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data[J]. Diabetes/Metabolism Research and Reviews, 2017, 33(8): e2924.
[11] Douros A, Lix L M, Fralick M, et al.Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study[J]. Annals of Internal Medicine, 2020, 173(6): 417-425.
[12] Juneja D, Nasa P, Jain R, et al.Sodium-glucose cotransporter-2 inhibitors induced euglycemic diabetic ketoacidosis: a meta summary of case reports[J]. World Journal of Diabetes, 2023, 14(8): 1314-1322.
[13] Dutta S, Kumar T, Singh S, et al.Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis[J]. Journal of Family Medicine and Primary Care, 2022, 11(3): 927-940.
[14] Cai Jun, Liu Si min, Li Huixin, et al. Literature analysis of dapag-liflozin-induced euglycemic diabetic ketoacidosis[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(11): 808-812.
[15] Gandecka-Pempera A, Naskręt D, Adamska A, et al.Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report[J]. Frontiers in Endocrinology (Lausanne), 2025, 16: 1649270.
[16] Briones-Claudett K H, Benites-Solis J, Delgado-Cedeño P, et al. Case report: high-altitude exposure and severe respiratory infection precipitating diabetic ketoacidosis: new-onset ketosis-prone diabetes unmasked by physiological stress[J]. Frontiers in Medicine (Lausanne), 2026, 13: 1762878.
[17] Center for drug evaluation, national medical products administration. Guidance for clinical evaluation of adverse event relevance in clinical trials (for trial implementation)[S]. Beijing: Center for Drug Evaluation, 2024.
[18] Shukla R, Shrestha P, Khanal B, et al.Euglycemic diabetic ketoacidosis: clinical suspicion and diagnosis[J]. Clinical Medicine Insights: Endocrinology and Diabetes, 2026, 19: 11795514261431390.
[19] Umpierrez G E, Davis G M, Elsayed N A, et al.Hyperglycemic crises in adults with diabetes: a consensus report[J]. Diabetes Care, 2024, 47(8): 1257-1275.
[20] Handelsman Y, Henry R R, Bloomgarden Z T, et al.American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis[J]. Endocrine Practice, 2016, 22(6): 753-762.
[21] Adeva-Andany M M, Adeva-Contreras L, Carneiro-Freire N, et al. The impact of high altitude (hypobaric hypoxia) on insulin resistance in humans[J]. Journal of Physiology and Biochemistry, 2025, 81(1): 35-55.

高原地区使用达格列净致正常血糖酮症酸中毒1例分析

One case of euglycemic diabetic ketoacidosis caused by dapagliflozin used at a high altitude

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	冯思琪, 倪雨晨, 胡冯译, 刘玥, 叶小飞, 郭晓晶. 细胞治疗产品上市后长期安全性监测的国际经验与中国优化路径[J]. 中国药物警戒, 2026, 23(9): 975-981.
[2]	刘红亮, 宋海波, 米岚, 孟康康, 王涛, 漆燕, 贾晋生. 基于大语言模型应用的个例安全性报告数据清洗方法探讨[J]. 中国药物警戒, 2026, 23(9): 1017-1022.
[3]	赵志伟, 柯文缘, 杨雪, 陈晓博, 夏旭东. 1358例碘克沙醇注射液不良反应报告分析[J]. 中国药物警戒, 2026, 23(9): 1040-1044.
[4]	潘恩, 崔小康, 徐滨, 荣右明, 范晓, 马晓东, 李霞. 1115例草酸艾司西酞普兰片不良反应报告分析[J]. 中国药物警戒, 2026, 23(9): 1045-1049.
[5]	尚家海, 龙娇娇, 刘雅瑞, 卢圆圆. 注射用尖吻蝮蛇血凝酶致儿童结膜充血2例分析[J]. 中国药物警戒, 2026, 23(9): 1050-1052.
[6]	吴倩, 覃勇, 望庐山, 韩忠宇. 吉非替尼片致心肌炎1例分析[J]. 中国药物警戒, 2026, 23(9): 1053-1055.
[7]	孙玲玲, 方薇, 王雨廷, 李进峰, 杨依磊. 阿昔洛韦咀嚼片致急性重度肝损伤1例分析[J]. 中国药物警戒, 2026, 23(9): 1056-1058.
[8]	王昆, 徐磊, 汪岑, 侯文平, 刘俊保, 苏长海. 地高辛片致舞蹈症1例分析[J]. 中国药物警戒, 2026, 23(9): 1059-1061.
[9]	邢璐宇, 邢迎红, 范文, 张淑翼. 注射用哌拉西林钠他唑巴坦钠致横纹肌溶解1例分析[J]. 中国药物警戒, 2026, 23(9): 1062-1064.
[10]	向群, 傅大莉. 药源性认知障碍的致病药物及疾病风险评估研究进展[J]. 中国药物警戒, 2026, 23(9): 1075-1080.
[11]	吕欣鸽, 刘艾嘉, 武一, 潘晨, 王雨婷, 崔向丽. 免疫检查点抑制剂相关甲状腺功能障碍的多中心病例分析[J]. 中国药物警戒, 2026, 23(8): 892-897.
[12]	李剑屏, 杜宁, 唐敏, 周子原, 左靖. 691例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2026, 23(8): 904-908.
[13]	白丽琴, 聂红科, 杨淑婷, 蒋晓峰. 214例肌苷注射液不良反应报告分析[J]. 中国药物警戒, 2026, 23(8): 909-913.
[14]	张育茂, 刘君波, 罗千江, 谭槟滢, 邓彬, 邢惟青, 李玉珍. 口服复方聚乙二醇电解质散（Ⅱ）肠道准备致呕血2例分析[J]. 中国药物警戒, 2026, 23(8): 931-933.
[15]	高朝政, 赵一帆, 苏丽, 李平. 注射用芦康沙妥珠单抗致癌症患者急性疼痛2例分析[J]. 中国药物警戒, 2026, 23(8): 934-937.